NK-cell
Showing 1 - 25 of >10,000
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)
Not yet recruiting
- NK Cell
- +2 more
- autologous NK cell
-
Hubei, Xiangyang, ChinaEC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023
Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)
Recruiting
- Aggressive NK Cell Leukemia
-
Hiroshima, JapanHiroshima University Hospital
May 9, 2023
Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)
Withdrawn
- Leukemia
- Donor Enriched Activated Natural Killer Cell Infusion
- (no location specified)
Dec 20, 2022
Colorectal Cancer Trial (anesthetic method)
Withdrawn
- Colorectal Cancer
- anesthetic method
- (no location specified)
Jul 11, 2023
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))
Recruiting
- Immunotherapy
- Multiple Myeloma
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Dec 14, 2022
Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 2, 2023
T-Cell and NK-Cell Tumor Trial
Not yet recruiting
- T-Cell and NK-Cell Neoplasm
- (no location specified)
Sep 28, 2023
Acute Myeloid Leukemia in Children Trial in Saint Louis (CIML NK Cell Infusion, CD3+ T Cell Product Infusion)
Recruiting
- Acute Myeloid Leukemia in Children
- CIML NK Cell Infusion
- CD3+ T Cell Product Infusion
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2022
Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)
Recruiting
- Peripheral T/NK Cell Lymphoma (R/R PTCL)
-
Houston, TexasMD Anderson Cancer Center
Oct 19, 2022
Acute Myeloid Leukemia Trial in Saint Louis (Graft cell infusion, Tacrolimus, Mycophenolate mofetil)
Recruiting
- Acute Myeloid Leukemia
- Graft cell infusion
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 29, 2023
Acute Myeloid Leukemia, MDS, Myeloproliferative Tumor Trial in Boston (CIML NK, Fludarabine, Cyclophosphamide)
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CIML NK
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 6, 2023
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15
Recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interleukin-15 Superagonist (N-803)
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 2, 2022
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)
Recruiting
- Lymphoma
- Radiation Therapy
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 9, 2022
Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- Ovarian Cancer
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Mar 26, 2023
Colon Cancer Stage I Trial in Taoyuan (Magicell-NK contains NK cells suspended in 100 mL normal saline)
Recruiting
- Colon Cancer Stage I
- Magicell-NK contains NK cells suspended in 100 mL normal saline
-
Taoyuan, TaiwanChang Gung Memorial Hospital, Linkou
Sep 28, 2022
AML Trial in Hangzhou (NKG2D CAR-NK)
Recruiting
- AML
- NKG2D CAR-NK
-
Hangzhou, Zhejiang, China
- +1 more
Feb 17, 2023
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed Trial in Tampa, Columbus (GEM/DOX + TGFBi expanded NK cells)
Recruiting
- Pediatric Sarcoma, Refractory
- Pediatric Sarcoma, Relapsed
- GEM/DOX + TGFBi expanded NK cells
-
Tampa, Florida
- +1 more
Jan 3, 2023
Biliary Tract Cancer Trial in Seoul ('SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda])
Completed
- Biliary Tract Cancer
- 'SMT-NK' Inj (allogeneic Natural Killer cell)
- Pembrolizumab Injection [Keytruda]
-
Seoul, Korea, Republic of
- +1 more
Mar 28, 2022
Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)
Recruiting
- Myeloid Malignancies
- Lymphoid Malignancies
- NK Cell enriched-DLI only
- NK-DLI + DUK-CPG-001
-
Durham, North CarolinaDuke University Health System
Mar 8, 2022
Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Supratentorial Tumor Trial in San Francisco (Universal Donor
Not yet recruiting
- Pediatric Brain Tumor
- +2 more
- Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
- Implantation
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 24, 2023